Insider Trading February 14, 2026

Avnet Executive Disposes $65,408 in Shares; Company Posts Better-Than-Expected Q2 Results

Chief Digital Officer Jay David Youngblood sold 987 shares on Feb. 12, 2026 as Avnet reported stronger-than-forecast earnings and revenue for fiscal Q2 2026

By Leila Farooq AVT
Avnet Executive Disposes $65,408 in Shares; Company Posts Better-Than-Expected Q2 Results
AVT

Jay David Youngblood, Avnet's Senior Vice President and Chief Digital Officer, sold 987 shares of company stock on February 12, 2026, for $66.27 per share, generating $65,408. Following the sale he retains 6,635 shares, which include 5,648 unvested restricted stock units. The transaction was reported on a Form 4 filing. Separately, Avnet posted fiscal second-quarter results that surpassed consensus estimates on both EPS and revenue.

Key Points

  • Jay David Youngblood sold 987 shares of Avnet on February 12, 2026 at $66.27 per share for a total of $65,408.
  • After the sale, Youngblood holds 6,635 Avnet shares, which include 5,648 RSUs that have been earned but are not yet vested or delivered.
  • Avnet reported fiscal Q2 2026 results with EPS of $1.05 (vs. $0.95 expected) and revenue of $6.3 billion (vs. $6.02 billion expected); analysts have noted the positive outcome, though no specific upgrades or downgrades were cited.

Avnet, Inc. reported an insider sale and a solid quarterly financial result in separate disclosures that underscore recent activity around the company's stock.

According to a Form 4 filing with the Securities and Exchange Commission, Jay David Youngblood, who serves as Senior Vice President and Chief Digital Officer at Avnet (NYSE: AVT), sold 987 shares of company stock on February 12, 2026. The sale was executed at $66.27 per share, producing a total transaction value of $65,408.

After completing the sale, Youngblood is recorded as directly owning 6,635 shares of Avnet. That total includes 5,648 shares that are underlying restricted stock units (RSUs) which have been earned but have not yet been vested or delivered.

The insider transaction was formally disclosed via the SEC's Form 4 process.


In related corporate news, Avnet released financial results for its second quarter of fiscal year 2026 that exceeded market expectations. The company reported earnings per share of $1.05, above the consensus estimate of $0.95. Revenue for the quarter came in at $6.3 billion versus a forecast of $6.02 billion. These figures reflect a quarter in which reported performance outpaced the estimates tracked by the market.

Analysts across various firms have taken note of Avnet's quarter, with some observers pointing to potential future growth. The company did not report any specific analyst upgrades or downgrades in connection with the results; however, the stronger-than-expected EPS and revenue could be a factor that influences future analyst assessments. Investors may weigh these developments when considering their positions.

Both the insider sale and the quarterly financial disclosure are now part of the public record; the Form 4 filing documents the share disposition, while the company-released results provide the latest operating snapshot for the fiscal second quarter of 2026.

Where information in the public filings or company release is limited, this account reflects only the details disclosed in those documents.

Risks

  • Analyst actions remain uncertain - the company reported stronger results but the article notes that no specific upgrades or downgrades were mentioned, which leaves potential analyst reactions unclear.
  • Investor interpretation of the insider sale may vary - while the sale is documented on a Form 4, the presence of substantial unvested RSUs in the executive's holdings could affect perceptions of the sale's significance.
  • Timing and vesting of RSUs - a large portion of the executive's reported holdings are unvested RSUs, which introduces uncertainty about when those shares could become liquid and potentially influence future share counts or insider transactions.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026